All In MedTech

Device Trial Radar · NCT05855135

Assessment of Combined CCM and ICD Device in HFrEF

Assessment of the Safety and Efficacy of a Combined Cardiac Contractility Modulation and Implantable Cardioverter Defibrillator Device for Subjects With Heart Failure and Reduced Ejection Fraction

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

300

Planned (sponsor's estimate)

Start

May 17, 2023

Primary completion

Dec 31, 2025

Study completion Jul 2027

Sponsor

Lead sponsor
Impulse DynamicsNot on our public-company list
Sponsor type
Industry
First posted
May 11, 2023

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to demonstrate that the OPTIMIZER® Integra CCM-D System (the "CCM-D System") can safely and effective convert induced ventricular fibrillation (VF) and spontaneous ventricular tachycardia and/or ventricular fibrillation (VT/VF) episodes in subjects with Stage C or D heart failure who remain symptomatic despite being on guideline-directed medical therapy (GDMT), are not indicated for cardiac resynchronization therapy (CRT), and have heart failure with reduced left ventricular ejection fraction (LVEF ≤40%). Eligible subjects will be implanted with the CCM-D System. A subset of subjects will be induced into ventricular fibrillation "on the table" in the implant procedure room. During the follow-up period, inappropriate shock rate and device-related complications will be evaluated. The follow-up period is expected to last at least two years.

Conditions

  • Heart Failure
  • Heart Failure With Reduced Ejection Fraction
  • Implantable Defibrillator User
  • CCM Therapy
  • Non-ischemic Cardiomyopathy
  • Ischemic Cardiomyopathy
  • Sudden Cardiac Arrest
  • Arrhythmias, Cardiac
  • Ventricular Tachycardia
  • Ventricular Fibrillation

Interventions

  • OPTIMIZER® Integra CCM-D System (Treatment Arm)Device

    The CCM-D System is an implantable cardiac device system that combines cardiac contractility modulation and implantable cardioverter defibrillator (ICD) modules into one device. CCM-D is also known as a "Cardiac Contractility Modulation - Defibrillator". All 300 subjects will be implanted with the CCM-D System and followed for a period of at least two years.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Device Effectiveness in Converting Induced Ventricular Fibrillation (Primary Efficacy Objective)Time frame: Implant
  2. Device-related Complications (Primary Safety Objective)Time frame: Implant to 6 months

Locations

59 sites in 1 country. Site status is shown where the registry gives one.

  • Phoenix Heart

    Glendale, Arizona

  • CardioVascular Associates of Mesa

    Mesa, Arizona

  • Southwest Cardiovascular Associates

    Mesa, Arizona

56 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.